Aelix Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $6.46M

  • Investors
  • 6

Aelix Therapeutics General Information

Description

Operator of a therapeutic vaccine biotechnology company intended to cure HIV infection. The company's vaccine is based on an observation of a T-cell immunogen that can elicit a strong broad and focused response against HIV and has the potential to radically transform the treatment of HIV infection, enabling patients to get cured of rare diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Biotechnology
Corporate Office
  • Parc Científic de Barcelona
  • Carrer Baldiri Reixac 4-8
  • 08028 Barcelona
  • Spain
+34 934 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aelix Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC 12-Jun-2018 $6.46M 000.00 000.00 Completed Generating Revenue
4. Early Stage VC 23-Nov-2017 00.000 00.00 000.00 Completed Generating Revenue
3. Grant 01-Jan-2017 00000 00.000 Completed Generating Revenue
2. Accelerator/Incubator 01-Jan-2017 $52.6K $4.36M Completed Generating Revenue
1. Early Stage VC (Series A) 11-Jan-2016 $4.36M $4.36M 00.00 Completed Generating Revenue
To view Aelix Therapeutics’s complete valuation and funding history, request access »

Aelix Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary Shares 0,000 00.000000 00000.0 00000.0 00 00000.0 00.000
Ordinary Shares 0,000 00.000000 00000.00 00000.00 00 00000.00 00.000
To view Aelix Therapeutics’s complete cap table history, request access »

Aelix Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a therapeutic vaccine biotechnology company intended to cure HIV infection. The company's vaccine is based o
Drug Discovery
Barcelona, Spain
6 As of 2024
000.00
000.00 0000-00-00
0000000000 0 000.00

000000

tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qui
0000 000000000
San Diego, CA
0 As of 0000
000.00
0000000000 0 000.00

000000

ed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad min
00000000000 0000000
Glasgow, United Kingdom
00 As of 0000
000.00
000.00 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aelix Therapeutics Competitors (33)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Viriom Venture Capital-Backed San Diego, CA 0 000.00 0000000000 0 000.00
Mironid Venture Capital-Backed Glasgow, United Kingdom 00 000.00 00000000000 000.00
GeoVax Labs Corporation Smyrna, GA 00 000.00 000000000 000.00
Kite Pharma Formerly VC-backed Santa Monica, CA 0000 00000 000000&0 00000
CaroGen Venture Capital-Backed Farmington, CT 00 00.000 0000000000 0 00.000
You’re viewing 5 of 33 competitors. Get the full list »

Aelix Therapeutics Patents

Aelix Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4058058-A1 Dosage regimens for vaccines Pending 14-Nov-2019 000000000
CA-3161633-A1 Dosage regimens for vaccines Pending 14-Nov-2019 000000000
AU-2020384323-A1 Dosage regimens for vaccines Pending 14-Nov-2019 000000000
US-20210145961-A1 Dosage regimens for vaccines Active 14-Nov-2019 000000000
US-11666651-B2 Prime/boost immunization regimen against hiv-1 utilizing a multiepitope t cell immunogen comprising gag, pol, vif, and nef epitopes Active 14-Nov-2019 A61K39/12 000
To view Aelix Therapeutics’s complete patent history, request access »

Aelix Therapeutics Executive Team (11)

Name Title Board Seat Contact Info
Christian Brander Ph.D Co-Founder & Chief Scientific Officer
Silvia López Director of Finance and Operations
Bonaventura Clotet Ph.D Co-Founder, Observer & Member of Scientific Advisory Board
Jordi Naval Co-Founder, Advisor & Board Member
Thomas Hecht Ph.D Executive Chairman & President
You’re viewing 5 of 11 executive team members. Get the full list »

Aelix Therapeutics Board Members (9)

Name Representing Role Since
Bonaventura Clotet Ph.D Aelix Therapeutics Co-Founder, Observer & Member of Scientific Advisory Board 000 0000
Buzz Benson Self Board Member 000 0000
Jordi Naval Aelix Therapeutics Co-Founder, Advisor & Board Member 000 0000
Karen Wagner Ph.D Ysios Capital Board Member 000 0000
Pablo Cironi Ph.D Caixa Capital Risc Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Aelix Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aelix Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
EIT Health Accelerator/Incubator 000 0000 000000 0
The Center for the Development of Industrial Technology Government 000 0000 000000 0
Caixa Capital Risc Venture Capital Minority 000 0000 000000 0
Criteria Bio Ventures Venture Capital Minority 000 0000 000000 0
Johnson & Johnson Innovation - JJDC Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Aelix Therapeutics FAQs

  • When was Aelix Therapeutics founded?

    Aelix Therapeutics was founded in 2015.

  • Who is the founder of Aelix Therapeutics?

    Christian Brander Ph.D, Bonaventura Clotet Ph.D, Josep Gatell, and Jordi Naval are the founders of Aelix Therapeutics.

  • Where is Aelix Therapeutics headquartered?

    Aelix Therapeutics is headquartered in Barcelona, Spain.

  • What is the size of Aelix Therapeutics?

    Aelix Therapeutics has 6 total employees.

  • What industry is Aelix Therapeutics in?

    Aelix Therapeutics’s primary industry is Drug Discovery.

  • Is Aelix Therapeutics a private or public company?

    Aelix Therapeutics is a Private company.

  • What is the current valuation of Aelix Therapeutics?

    The current valuation of Aelix Therapeutics is 000.00.

  • What is Aelix Therapeutics’s current revenue?

    The current revenue for Aelix Therapeutics is 000000.

  • How much funding has Aelix Therapeutics raised over time?

    Aelix Therapeutics has raised $13.2M.

  • Who are Aelix Therapeutics’s investors?

    EIT Health, The Center for the Development of Industrial Technology, Caixa Capital Risc, Criteria Bio Ventures, and Johnson & Johnson Innovation - JJDC are 5 of 6 investors who have invested in Aelix Therapeutics.

  • Who are Aelix Therapeutics’s competitors?

    Viriom, Mironid, GeoVax Labs, Kite Pharma, and CaroGen are some of the 33 competitors of Aelix Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »